Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug ...

(MENAFN- Caribbean News Global) GENEVA, Switzerland – WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable lenacapavir as pre ...

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma.

The firm highlighted that Gilead's shares have seen a rise due to positive developments in its pipeline, particularly for Lenacapavir in HIV prevention and anito-cel in multiple myeloma. Gilead's ...

Addressing stigma, inequity, and access to HIV innovations remains critical to progress in the global HIV response, says IAS ...

Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...

Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV ...

Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees ...

Gilead Sciences (GILD – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Terence Flynn ...

The Dow Jones Industrial Average lost 696.75 points, or 1.63%, to close at 41,938.45. The S&P 500 slid 1.54% to 5,827.04, ...

JP Morgan highlights mixed sentiment for U.S. large-cap biopharma stocks as advancements in obesity drugs and key product launches shape 2025 outlook.